Among the highlights of WCLC are final overall survival (OS) data from AstraZeneca's FLAURA 2 study of EGFR inhibitor Tagrisso (osimertinib) given in combination with chemotherapy as a first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback